Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bissonnette

Showing results (201-210 of 223) with videos related to

Pageof 23
Sort By:
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
Journal of the American Academy of Dermatology|May 22, 2024
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsJonathan I Silverberg, Lawrence F Eichenfield, Adelaide A Hebert, et al.
NEJM Evidence|November 5, 2025
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact SitesMelinda Gooderham, Edward Lain, Robert Bissonnette, et al.
Allergy|April 18, 2021
Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 responseAxel P Villani, Ana B Pavel, Jianni Wu, et al.
Journal of Drugs in Dermatology : JDD|February 6, 2023
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept StudyMelinda Gooderham, Leon Kircik, Matthew Zirwas, et al.
Journal of the American Academy of Dermatology|December 15, 2022
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohortKatrina Abuabara, Lawrence F Eichenfield, Robert Bissonnette, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 13, 2023
Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitisYael Renert-Yuval, Ester Del Duca, Bernd Arents, et al.
Allergy|December 18, 2023
Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitisEmma Guttman-Yassky, Paola Facheris, Pedro Jesus Gomez-Arias, et al.
JAMA Dermatology|March 9, 2022
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical TrialsEric L Simpson, Kim A Papp, Andrew Blauvelt, et al.
The Journal of Allergy and Clinical Immunology|September 9, 2018
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitisEmma Guttman-Yassky, Robert Bissonnette, Benjamin Ungar, et al.
Pageof 23

Showing results (201-210 of 223) with videos related to

Sort By:
Pageof 23
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
Journal of the American Academy of Dermatology|May 22, 2024
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsJonathan I Silverberg, Lawrence F Eichenfield, Adelaide A Hebert, et al.
NEJM Evidence|November 5, 2025
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact SitesMelinda Gooderham, Edward Lain, Robert Bissonnette, et al.
Allergy|April 18, 2021
Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 responseAxel P Villani, Ana B Pavel, Jianni Wu, et al.
Journal of Drugs in Dermatology : JDD|February 6, 2023
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept StudyMelinda Gooderham, Leon Kircik, Matthew Zirwas, et al.
Journal of the American Academy of Dermatology|December 15, 2022
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohortKatrina Abuabara, Lawrence F Eichenfield, Robert Bissonnette, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 13, 2023
Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitisYael Renert-Yuval, Ester Del Duca, Bernd Arents, et al.
Allergy|December 18, 2023
Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitisEmma Guttman-Yassky, Paola Facheris, Pedro Jesus Gomez-Arias, et al.
JAMA Dermatology|March 9, 2022
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical TrialsEric L Simpson, Kim A Papp, Andrew Blauvelt, et al.
The Journal of Allergy and Clinical Immunology|September 9, 2018
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitisEmma Guttman-Yassky, Robert Bissonnette, Benjamin Ungar, et al.
Pageof 23